The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Accelerated diabetic glomerulopathy in galectin‐3/AGE receptor 3 knockout mice
Abstract
Several molecules were shown to bind advanced glycation end products (AGEs) in vitro, but it is not known whether they all serve as AGE receptors and which functional role they play in vivo. We investigated the role of galectin‐3, a multifunctional lectin with (anti)adhesive and growth‐regulating properties, as an AGE receptor and its contribution to the development of diabetic glomerular disease, using a knockout mouse model. Galectin‐3 knockout mice obtained by gene ablation and the corresponding wild‐type mice were rendered diabetic with streptozotocin and killed 4 months later, together with age‐matched nondiabetic controls. Despite a comparable degree of metabolic derangement, galectin‐3‐deficient mice developed ac‐celerated glomerulopathy vs. the wild‐type animals, as evidenced by the more pronounced increase in protein‐uria, extracellular matrix gene expression, and mesan‐gial expansion. This was associated with a more marked renal/glomerular AGE accumulation, indicating it was attributable to the lack of galectin‐3 AGE receptor function. The galectin‐3‐deficient genotype was associated with reduced expression of receptors implicated in AGE removal (macrophage scavenger receptor A and AGE‐R1) and increased expression of those mediating cell activation (RAGE and AGE‐R2). These results show that the galectin‐3‐regulated AGE receptor pathway is operating in vivo and protects toward AGE‐induced tissue injury in contrast to that through RAGE.—Pugliese, G., Pricci, F., Iacobini, C., Leto, G., Amadio, L., Barsotti, P., Frigeri L., Hsu, D. K., Vlassara, H., Liu, F.‐T., Di Mario, U. Accelerated diabetic glomerulopathy in galectin‐3/AGE receptor 3 knockout mice. FASEB J . 15, 2471–2479 (2001)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17810 · Cited by 813
Vlassara, H., Li, Y. M., Imani, F., Wojciechowicz, D., Yang, Z., Liu, F.-T., & Cerami, A. (1995) · Molecular Medicine · doi:10.1007/bf03401604 · Cited by 421
Self-citationSasaki, N., Toki, S., Chowei, H., Saito, T., Nakano, N., Hayashi, Y., Takeuchi, M., & Makita, Z. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03075-4 · Cited by 253
Cited by
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
“Review Article Role of advanced glycation end products in cellular signaling$ Christiane Ott a,1, Kathleen Jacobs b,1, Elisa Haucke c,1, Anne Navarrete Santos c, Tilman Grune a, Andreas Simmb,n a Department of Nutritional Toxicology, Institute of Nutrition, Friedrich Schiller University Jena, 07743 Jena, Germany b Cli…”
BackgroundInfluentialDietary factors and low-grade inflammation in relation to overweight and obesity
Calder, P. C., Ahluwalia, N., Brouns, F., Buetler, T., Clement, K., Cunningham, K., Esposito, K., Jönsson, L. S., Kolb, H., Lansink, M., et al. (2011) · British Journal of Nutrition · doi:10.1017/s0007114511005460 · Cited by 1,098
Self-citationThe Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Galectins: structure, function and therapeutic potential
Yang, R.-Y., Rabinovich, G. A., & Liu, F.-T. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000719 · Cited by 862
Self-citationDiabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Self-citationThe regulation of inflammation by galectin‐3
Henderson, N. C., & Sethi, T. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00794.x · Cited by 522
Galectins: regulators of acute and chronic inflammation
Liu, F., & Rabinovich, G. A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05131.x · Cited by 405
Self-citationAdvanced glycation end products and the kidney
Bohlender, J. M., Franke, S., Stein, G., & Wolf, G. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00398.2004 · Cited by 387
Changes in aqueous humor dynamics with age and glaucoma
Gabelt, B. T., & Kaufman, P. L. (2005) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.10.003 · Cited by 377
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G., Bellotti, C., Salehi, L., & Ricci, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020379 · Cited by 377
Advanced glycation endproducts: what is their relevance to diabetic complications?
Ahmed, N., & Thornalley, P. J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00595.x · Cited by 371
Extracellular functions of galectin-3
Ochieng, J., Furtak, V., & Lukyanov, P. (2002) · Glycoconjugate Journal · doi:10.1023/b:glyc.0000014082.99675.2f · Cited by 370
AGE, RAGE, and ROS in Diabetic Nephropathy
Tan, A. L. Y., Forbes, J. M., & Cooper, M. E. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.006 · Cited by 368
Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms
Stirban, A., Gawlowski, T., & Roden, M. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.11.006 · Cited by 361
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Self-citationYamagishi, S.-I. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.007 · Cited by 302
Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update
Bhattacharjee, N., Barma, S., Konwar, N., Dewanjee, S., & Manna, P. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.022 · Cited by 271
Lu, C., He, J. C., Cai, W., Liu, H., Zhu, L., & Vlassara, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401588101 · Cited by 228
Self-citationMaillard-Lefebvre, H., Boulanger, E., Daroux, M., Gaxatte, C., Hudson, B. I., & Lambert, M. (2009) · Rheumatology · doi:10.1093/rheumatology/kep199 · Cited by 190
Scavenger Receptors that Recognize Advanced Glycation End Products
Miyazaki, A. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00171-8 · Cited by 113
Role of galectin-3 in diabetic nephropathy
Iacobini, C., Amadio, L., Oddi, G., Ricci, C., Barsotti, P., Missori, S., Sorcini, M., Di Mario, U., Pricci, F., & Pugliese, G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000077402.95720.b4 · Cited by 99
Self-citationIacobini, C., Menini, S., Ricci, C., Scipioni, A., Sansoni, V., Cordone, S., Taurino, M., Serino, M., Marano, G., Federici, M., et al. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.186791 · Cited by 91
Self-citation
Metadata
- Authors
- PUGLIESE, G., PRICCI, F., IACOBINI, C., LETO, G., AMADIO, L., BARSOTTI, P., FRIGERI, L., HSU, D. K., VLASSARA, H., LIU, F.-T., & DI MARIO, U.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2001-11
- Volume
- 15
- Issue
- 13
- Pages
- 2471-2479
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2142233913
- Cited by
- 184
- References
- 4
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.